Zika vaccine: early data demonstrate safety, immunogenicity

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preliminary data show that a purified formalin-inactivated Zika virus (ZIKV) vaccine (ZPIV) has a good tolerability profile, and provides sufficient immunogenicity to offer clinical protection against ZIKV.
  • Initial data support larger, more advanced trials to further establish clinical benefit.

Why this matters

  • Although ZIKV outbreaks are mostly over, the threat of resurgent and unpredictable epidemics remains; reports continue to evolve documenting viral shedding and persistence, as well as poor congenital outcomes.
  • Clinicians should continue to counsel patients suspected of ZIKV exposure or planning to become pregnant on prevention, sexual transmission, and fetal outcomes.

Key results

  • 67 individuals vaccinated with 2 ZPIV doses, 12 with placebo, followed to day 57.
  • No clinically meaningful adverse events (AEs) were reported (84% [n=56] reported 1 AEs after first, second, or both doses; most were mild/moderate).
  • Neutralizing antibodies were elicited in almost all participants at 2-4 weeks after second dose.
  • Primary immunogenicity endpoint (geometric mean titers) reached peak by day 43; 92% (n=48) seroconverted after second dose at peak 1:10 threshold.

Study design

  • Aggregate analysis of 3 single-center, placebo-controlled, double-blind trials to determine safety, immunogenicity of ZPIV in flavivirus-naive (infection or vaccination) adults.
  • Funding: Departments of the Army and Defense; National Institute of Allergy and Infectious Diseases.

Limitations

  • Short-term follow-up.